OBJECTIVE: Description of the various autoantibodies that can be detected in patients with systemic lupus erythematosus (SLE). METHODS: A literature review, using the terms "autoantibody" and "systemic lupus erythematosus", was conducted to search for articles on autoantibodies in SLE, their target antigens, association with disease activity, or other clinical associations. RESULTS: One hundred sixteen autoantibodies were described in SLE patients. These include autoantibodies that target nuclear antigens, cytoplasmic antigens, cell membrane antigens, phospholipid-associated antigens, blood cells, endothelial cells, and nervous system antigens, plasma proteins, matrix proteins, and miscellaneous antigens. The target of autoantibody, the autoantigen properties, autoantibody frequencies in SLE, as well as clinical associations, and correlation with disease activity are described for all 116 autoantibodies. CONCLUSIONS: SLE is the autoimmune disease with the largest number of detectable autoantibodies. Their production could be antigen-driven, the result of polyclonal B cell activation, impaired apoptotic pathways, or the outcome of idiotypic network dysregulation.
OBJECTIVE: Description of the various autoantibodies that can be detected in patients with systemic lupus erythematosus (SLE). METHODS: A literature review, using the terms "autoantibody" and "systemic lupus erythematosus", was conducted to search for articles on autoantibodies in SLE, their target antigens, association with disease activity, or other clinical associations. RESULTS: One hundred sixteen autoantibodies were described in SLEpatients. These include autoantibodies that target nuclear antigens, cytoplasmic antigens, cell membrane antigens, phospholipid-associated antigens, blood cells, endothelial cells, and nervous system antigens, plasma proteins, matrix proteins, and miscellaneous antigens. The target of autoantibody, the autoantigen properties, autoantibody frequencies in SLE, as well as clinical associations, and correlation with disease activity are described for all 116 autoantibodies. CONCLUSIONS:SLE is the autoimmune disease with the largest number of detectable autoantibodies. Their production could be antigen-driven, the result of polyclonal B cell activation, impaired apoptotic pathways, or the outcome of idiotypic network dysregulation.
Authors: Joanne A O'Donnell; Jesse Lehman; Justine E Roderick; Dalia Martinez-Marin; Matija Zelic; Ciara Doran; Nicole Hermance; Stephen Lyle; Manolis Pasparakis; Katherine A Fitzgerald; Ann Marshak-Rothstein; Michelle A Kelliher Journal: J Immunol Date: 2017-12-06 Impact factor: 5.422
Authors: Adel A Shabana; Atef E El-Ghawet; Shereen A Machaly; Ekbal M Abu Hashim; Basma A El-Kady; Reham Shaat Journal: Clin Rheumatol Date: 2009-03-14 Impact factor: 2.980
Authors: Yi Ting Koh; John C Scatizzi; Jennifer D Gahan; Brian R Lawson; Roberto Baccala; K Michael Pollard; Bruce A Beutler; Argyrios N Theofilopoulos; Dwight H Kono Journal: J Immunol Date: 2013-04-15 Impact factor: 5.422